MarketCap
Facebook
X
Telegram
Intra-Cellular Therapies Income Statement 2024-2011 | ITCI
Brief overview of financial performance at Intra-Cellular Therapies
The figures are compared over a five-year interval. Revenue at Intra-Cellular Therapies moved from 60.6 thousand dollars in 2019 to 199 million dollars in 2024. Overall revenue changed by +328580.3%, equal to an annualized rate of about 405.1%. Revenue growth reflects a pronounced phase of business expansion.
Over the period, EBITDA shifted from −$154 million to −$116 million, a change of +24.3%. Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was −253303.3% at the start and −58.3% at the end. The increased EBITDA share is a positive sign.
Comparing the endpoints shows a move from −$148 million to −$16.9 million. The negative result improved without reaching break-even.
Market value was $1.3 billion at the start and $13.3 billion at the end. The market value rose well beyond the pace of financial improvement.
Overall conclusion
The figures do not all move in the same direction. The positive side is supported by improving net profitability, sales growth and an improving EBITDA margin. The most visible risks are a low EBITDA margin. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Intra-Cellular Therapies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
13.3 B | 6.77 B | 4.64 B | 4.25 B | 2.24 B | 1.27 B | 639 M | 787 M | 576 M | 1.34 B | 556 M | 328 M | - | - |
Shares |
103 M | 95.9 M | 94 M | 81.3 M | 70.4 M | 55.2 M | 54.7 M | 46.2 M | 43.2 M | 36.1 M | 28.7 M | 17.3 M | - | - |
Historical Prices |
129 | 70.6 | 49.3 | 52.3 | 31.8 | 34.3 | 11.4 | 14.5 | 15.1 | 53.8 | 17.6 | - | - | - |
Net Income |
-16.9 M | -28.6 M | -256 M | -284 M | -227 M | -148 M | -155 M | -97.8 M | -116 M | -105 M | -30.7 M | -32.1 K | -16.6 M | - |
Revenue |
199 M | 132 M | 250 M | 83.8 M | 22.8 M | 60.6 K | - | 246 K | 331 K | 91.4 K | 577 K | - | 3.12 M | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | 91.4 K | 577 K | - | 3.12 M | - |
Operating Income |
-117 M | -159 M | -264 M | -286 M | -231 M | -154 M | -162 M | -103 M | -118 M | -106 M | -31 M | -26.3 M | -16.4 M | - |
Interest Expense |
- | - | - | - | - | - | - | - | 36.8 K | - | 7.07 K | 613 K | 193 K | - |
EBITDA |
-116 M | -159 M | -263 M | -285 M | -231 M | -154 M | -162 M | -103 M | -118 M | -106 M | -31 M | - | -16.4 M | - |
Operating Expenses |
228 M | 166 M | 514 M | 369 M | 254 M | 154 M | 162 M | 103 M | 119 M | 106 M | 31.6 M | - | 19.5 M | - |
General and Administrative Expenses |
504 M | 410 M | 359 M | 273 M | 186 M | 64.9 M | 30.1 M | 23.7 M | 24.8 M | 18.2 M | 10.3 M | - | 4.03 M | - |
All numbers in USD currency
Quarterly Income Statement Intra-Cellular Therapies
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
106 M | 104 M | 96.9 M | 96.4 M | 96.1 M | 95.9 M | 95.1 M | 94.8 M | 94.5 M | 94.3 M | 92.6 M | 81.9 M | 81.4 M | 81.2 M | 80.9 M | 80.5 M | 69.5 M | 66.4 M | 65.1 M | 55.5 M | 55.2 M | 55.1 M | 55.1 M | 54.9 M | 54.7 M | 54.7 M | 54.7 M | 54.6 M | 43.4 M | 43.4 M | 43.4 M | 43.3 M | 43.3 M | 43.2 M | 43.2 M | 43.2 M | 35.3 M | 35 M | 30.8 M | 29.5 M | 29.4 M | 29.3 M | 26.5 M | 22.2 M | 11.8 M | 14.7 M | 5 M | 14.6 M | 5.61 M | - | - | - | - | - | - |
Net Income |
-26.3 M | -16.2 M | -15.2 M | - | -24.3 M | -42.8 M | -44.1 M | - | -53.5 M | -86.6 M | -72.1 M | -85.7 M | -76.9 M | -68.7 M | -52.7 M | -60.7 M | -55.2 M | -63.7 M | -47.4 M | -40.6 M | -34.9 M | -37.4 M | -34.8 M | -40.7 M | -41.5 M | -37.4 M | -35.5 M | -30.2 M | -22.9 M | -17.8 M | -26.9 M | -27.5 M | -30.3 M | -30.8 M | -27.8 M | -28.8 M | -32.2 M | -21.5 M | -22.3 M | -15.2 M | -6.42 M | -4.53 M | -4.54 M | -8.04 M | -18.8 M | -8.28 M | -10.9 K | - | -15.4 M | - | - | - | - | - | - |
Revenue |
175 M | 161 M | 145 M | - | 126 M | 111 M | 95.3 M | - | 71.9 M | 55.6 M | 35 M | 25.7 M | 22.2 M | 20 M | 15.9 M | 12.5 M | 7.37 M | 1.91 M | 1.08 M | 60.6 K | - | - | - | - | 30.8 K | 115 K | 95.3 K | 5.06 K | 30.8 K | 115 K | 95.3 K | 97.9 K | 4.36 K | 228 K | 3.32 K | 30.7 K | 60.7 K | 57.4 K | 3.32 K | 65.9 K | 124 K | 219 K | 168 K | 828 K | 668 K | 643 K | 598 K | - | 378 K | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 69 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-38.8 M | -27.7 M | -21 M | - | -29.7 M | -47.2 M | -48.4 M | - | -55.6 M | -87.9 M | -72.7 M | - | -77.3 M | -69.1 M | -53.2 M | - | -55.9 M | -64.9 M | -49.1 M | - | -36.4 M | -39.2 M | -36.7 M | - | -43.4 M | -39.2 M | -37.1 M | - | -23.8 M | -18.6 M | -27.8 M | - | -30.2 M | -31.5 M | -28.5 M | - | -32.3 M | -21.7 M | -22.4 M | - | -6.5 M | -4.61 M | -4.57 M | - | -4.79 M | -8.05 M | -10.8 K | - | -2.22 M | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.3 K | - | - | - | 12.3 K | - | - | - | 7.07 K | 2.03 K | 5.04 K | - | 7.07 K | 2.03 K | 5.04 K | - | 132 K | 232 K | 65 | - | - | - | - | - | - | - | - |
EBITDA |
-38.4 M | -27.5 M | -20.8 M | - | -29.3 M | -46.9 M | -48.3 M | - | -55.1 M | -87.6 M | -72.5 M | - | -77.2 M | -69 M | -53.1 M | - | -55.8 M | -64.7 M | -48.9 M | - | -36 M | -39 M | -36.6 M | - | -43.1 M | -39 M | -37 M | - | -23.6 M | -18.5 M | -27.7 M | - | -30 M | -31.4 M | -28.4 M | - | -32.3 M | -21.6 M | -22.4 M | - | -6.5 M | -4.61 M | -4.57 M | - | -4.78 M | -8.04 M | -4.62 K | - | -2.18 M | - | - | - | - | - | - |
Operating Expenses |
214 M | 189 M | 166 M | - | 156 M | 158 M | 144 M | - | 127 M | 144 M | 108 M | 112 M | 99.5 M | 89.2 M | 69.1 M | 73.8 M | 63.3 M | 66.8 M | 50.2 M | 41.8 M | 36.4 M | 39.2 M | 36.7 M | - | 43.4 M | 39.2 M | 37.1 M | - | 23.8 M | 18.7 M | 27.8 M | - | 30.2 M | 31.8 M | 28.5 M | - | 32.3 M | 21.7 M | 22.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
132 M | 122 M | 113 M | - | 105 M | 101 M | 98.9 M | - | 88.4 M | 100 M | 75.5 M | - | 70.5 M | 69.9 M | 52.6 M | - | 52.5 M | 41.4 M | 34.1 M | - | 15 M | 15.4 M | 11.7 M | - | 7.97 M | 6.73 M | 6.38 M | - | 5.32 M | 6.25 M | 6.31 M | - | 6.27 M | 6.47 M | 5.06 M | - | 3.89 M | 3.99 M | 3.77 M | - | 2.58 M | 2.12 M | 1.91 M | - | 1.3 M | 903 K | 10.8 K | - | 802 K | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Intra-Cellular Therapies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
